About
Fasikl is a Neuro-AI company headquartered in Minnesota, dedicated to developing innovative AI therapies that provide patients and physicians with a new, more effective, safer, and personalized approach to treating diseases.
The Technology
Fasikl’s products are built on patented technologies designed to enhance efficiency and precision in communicating with the nervous system. By integrating NeuroAI algorithms, we empower existing neuromodulation therapies to achieve greater efficacy and safety, leading the way into the era of AI therapeutics.
Clinical Outcomes
Felix, our first AI therapy product, has undergone rigorous clinical trials. Unlike typical medical devices, Felix has been evaluated through a double-blind, randomized, sham-controlled study to thoroughly validate its efficacy and safety.
People
Zhi Yang
CEO & Co-founder
Zhi Yang, Ph.D., is a world-renowned expert in neural engineering and bioelectronics. He earned his Ph.D. from the University of California, Santa Cruz, began his faculty career at the National University of Singapore in 2010, and joined the University of Minnesota in 2015, where he was tenured in 2019. Dr. Yang has made foundational contributions to AI therapeutics, including technologies for single-fascicle resolution neural recordings, recording during therapeutic stimulation, and the integration of recording, processing, and stimulation—laying the groundwork for AI-driven therapy. He co-founded Fasikl and has led the development and execution of its business strategy, technological innovation, and overall direction. Since 2020, he has served as the company’s CEO and Chairman of the Board.
Zhen Zhang
President
Zhen Zhang, Ph.D., leads Fasikl’s clinical, regulatory, and quality operations. Before joining Fasikl, Dr. Zhang led all pre-market clinical programs of Abbott’s cardiovascular division. His significant contributions in clinical and regulatory affairs earned him induction into Abbott’s prestigious Volwiler Society. With over 18 years of experience in the medtech industry, Dr. Zhang possesses deep expertise in clinical and regulatory affairs. He has played a pivotal role in conducting over 10 IDE trials and securing approvals for multiple Class II and Class III devices. Dr. Zhang has extensive experience working with the U.S. FDA (510(k), IDE, PMA, panel meeting) as well as global regulatory agencies. He is a widely published author in top medical journals including The New England Journal of Medicine and The Lancet.
Edward Keefer
Chief Scientific Officer & Co-founder
Edward Keefer, Ph.D., is an experimental neuroscientist who trained under Nobel Laureate Gerald Edelman and contributed to Defense Advanced Research Projects Agency (DARPA) projects for over 15 years. He developed intrafascicular LIFE electrodes for human implantation, pioneered related surgical techniques, and advanced the physiological understanding necessary to treat neurological disorders through electrical stimulation. Dr. Keefer leads neuroscientific and physiological research at Fasikl, focusing on advancing therapeutic outcomes.
Catherine Zhao
Chief AI Officer
Catherine Zhao, Ph.D., is an accomplished computer scientist specializing in AI, with expertise in computer vision, machine learning, and human-centered AI. Her work focuses on developing application-specific machine learning methods and creating trustworthy systems that integrate both artificial and human intelligence. Her notable contributions include pioneering the use of deep learning for autism screening, developing the first deep learning model to decode human motor intention, and creating NeuroAI algorithms to optimize therapeutic stimulation. Dr. Zhao leads the AI team at Fasikl, where she drives cutting-edge innovation in therapeutic AI technologies.
